No quarterly revenue total was found in CULLINAN THERAPEUTICS, INC.'s SEC filings.
Cullinan Therapeutics, Inc. (CGEM) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $353.6 million in cash and investments and $2.1 million in total debt.
Revenue
—
Net income
$-53.70M
+23.3% vs year-ago quarter
Operating cash flow
$-38.22M
+33.7% vs year-ago quarter
Free cash flow
$-38.12M
-4.1% vs year-ago quarter
EPS
$-0.69
Dividend per share
None
Shares outstanding
64.35M
+8.9% vs year-ago quarter
Net cash
$351.49M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CGEM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1789972
- Former names
- Cullinan Oncology, Inc. (until Apr 2, 2024); Cullinan Management, Inc. (until Feb 22, 2021); Cullinan Oncology, LLC (until Jan 6, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$57.3M | -$53.7M | -$55.3M | -$55.6M | -$75.8M |
| Net income | -$53.7M | -$49.7M | -$50.7M | -$50.6M | -$70.1M |
| Operating cash flow | -$38.2M | -$46.0M | -$38.1M | -$36.9M | -$57.6M |
| Free cash flow | — | — | -$38.1M | -$36.9M | — |
| Total assets | $363.8M | $403.0M | $448.4M | $484.1M | $520.3M |
| Total liabilities | $42.0M | $36.8M | $39.6M | $32.8M | $28.2M |
| Stockholders' equity | $321.8M | $366.2M | $408.7M | $451.4M | $492.1M |
| Cash and investments | $353.6M | $390.4M | $436.2M | $472.6M | $507.8M |
| Total debt | $2.1M | $2.4M | $2.7M | $1.2M | $1.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 2, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 24, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 14, 2026 | Sep 13, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 13, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
All 465 Cullinan Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.